PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma

PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma

Abstract Background The treatment for advanced primary hepatocellular carcinoma (HCC) is sorafenib (SORA), while HCC has become increasingly drug resistant with enhanced aerobic glycolysis. The present study aimed to examine the chemotherapeutic effects of a flavonoid proanthocyanidin B2 (PB2) on HC...

Full description

Bibliographic Details
Main Authors: Jiao Feng, Liwei Wu, Jie Ji, Kan Chen, Qiang Yu, Jie Zhang, Jiaojiao Chen, Yuqing Mao, Fan Wang, Weiqi Dai, Ling Xu, Jianye Wu, Chuanyong Guo
Format: Article
Language:English
Published: BMC 2019-05-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Proanthocyanidin B2
Hepatocellular carcinoma
Aerobic glycolysis
PKM2
Sorafenib
Online Access:http://link.springer.com/article/10.1186/s13046-019-1194-z

Internet

http://link.springer.com/article/10.1186/s13046-019-1194-z

Similar Items